Abstract
Background/Aim Treatment with growth factors could be beneficial in both inflammatory bowel disease and experimental colitis. The aim of this study was to investigate the effect of Colony Stimulating Factor (CSF), and Recombinant Human (rHu) Granulocyte Stimulating Factor (GSF) in experimental colitis in rats. Methods Experimental colitis was induced in 62 male Wistar rats, divided into 9 groups, using 2,4,6-trinitrobenzensulfonic acid (TNBS). Group 1: Ten rats with colitis without treatment (control group). Euthanasia after 15 days. Group 2: Ten animals with colitis without treatment (control group). Euthanasia after 30 days. Group 3: Six animals with colitis. Immediate treatment with CSF. Euthanasia after 19 days. Group 4: Six animals with colitis. Treatment started 7 days after the induction of colitis. Animals were kept for 19 days. Group 5: Six animals with colitis. Treatment started 2 weeks after the induction of colitis. Group 6: Six animals with colitis, the same as in group 3. Treatment with GSF. Group 7: Six animals with colitis, the same as in group 4. Treatment with GSF. Group 8 Six animals with colitis, the same as in group 5. Treatment with GSF. Group 9: Six animals with colitis. Immediate treatment with prednisolone. Euthanasia after 15 days. Results CSF and GSF administration significantly improved the histological score (P < 0.05) and reduced malondialdehyde contents (P < 0.05), compared to control groups in all animals. CSF was superior to GSF and to prednisolone. Conclusion Administration of both CSF and GSF could significantly improve the histological score and oxidative stress in experimental colitis in rats.
Highlights
In ammatory bowel disease (IBD) is a chronic and relapsing in ammatory disorder of the gastrointestinal with two main entities, Crohn’s Disease (CD) and Ulcerative Colitis (UC).e primary therapeutic goals are improvement of quality of life through induction and maintenance of remission, prediction, prevention, and treatment of complications, restoration of nutritional de cits, and alteration of the natural history of the disease [1]
T 1: Experimental Trinitrobenzenesulfonic acid (TNBS) colitis in 62 male Wistar rats treated with CSF, GM-CSF and prednizolone, divided into 9 groups according to our experimental protocol
Distal colitis was induced by intracolonic installation of 25 mg of TNBS dissolved in 0.25 mL of 50% ethanol. e solution was injected into the colon 8 cm proximal to the anus with a PE-50 cannula
Summary
In ammatory bowel disease (IBD) is a chronic and relapsing in ammatory disorder of the gastrointestinal with two main entities, Crohn’s Disease (CD) and Ulcerative Colitis (UC). Recombinant human Granulocyte-Macrophage Colony Stimulating Factor [GM-CSF (rHu GM-CSF)] [molgramostim (Mielogen)] is a human protein produced by a strain of BioMed Research International. Lenograstim is the glycosylated recombinant form of human granulocyte colony stimulating factor with actions similar to those of molgramostim. Of the currently in use animal models, the 2,4,6-Trinitrobenzenesulfonic acid (TNBS) induced colitis, resembles human IBD in its various histological features, including infiltration of colonic mucosa by neutrophils and macrophages and increased production of inflammatory mediators [5,6,7]. E aim of this study was to investigate the influence of the two growth factors; Granulocyte-Colony Stimulating Factor (G-CSF, Lenograstim), and recombinant human Granulocyte-Macrophage Colony Stimulating Factor, (rHu GM-CSF, Molgramostim, Mielogen)], as possible therapeutic agents in experimental colitis in rats
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
